FDA Affirms Off-Label Dissemination Policy In Denial of WLF Petition
Executive Summary
Dissemination of off-label journal reprints alone is "unlikely" to trigger enforcement action against a drug or medical device manufacturer, FDA says
You may also be interested in...
Pfizer To Monitor Off-Label Drug Use Under Neurontin Settlement
Pfizer will provide periodic reports to the HHS Inspector General about off-label use trends for its products under the May 13 settlement of an investigation into the company's promotion of Neurontin
Pfizer To Monitor Off-Label Drug Use Under Neurontin Settlement
Pfizer will provide periodic reports to the HHS Inspector General about off-label use trends for its products under the May 13 settlement of an investigation into the company's promotion of Neurontin
“Brief Summary” Requirement Is Legally Vulnerable, Attorney Tells WLF
FDA's policy that a brief summary must accompany print advertising is vulnerable to legal challenge, attorney Richard Frank (Olsson, Frank & Weeda) declared during a Washington Legal Foundation briefing on First Amendment issues May 30